Nykode has been granted a patent for the company’s individualized cancer vaccine VB10.NEO, which is being developed for the treatment of locally advanced or metastatic solid tumors.
The patent’s 20-year expiry date is January 5, 2037, the company said in a stock exchange announcement. Nykode has previously been granted related patents in Russia, India and Australia.
Michael Engsig, CEO of Nykode, believes the patent proves that Nykode is engaged in “world-class innovation”:
”’We are very pleased with the granting of this important patentin the U.S., a key market for Nykode. Continuously expanding our patent protection is a core strategy for us. The granting of this patent is a testament to the world-class innovation taking place in Nykode’s labs.,” says Michael Engsig, CEO of Nykode.
The VB10:NEO vaccine is being developed in collaboration with Genentech, a member of the Roche Group.
A clinical trial evaluating VB10:NEO: VB N- is currently underway.
English edit: Simon Øst Vejbæk
